BiomX to Present at the Cantor Fitzgerald Global Healthcare Conference
NESS ZIONA, Israel, Sept. 30, 2019 /PRNewswire/ -- BiomX Ltd., a microbiome company developing both natural and engineered phage therapies, today announced that BiomX's Chief Executive Officer, Jonathan Solomon, will present at the Cantor Fitzgerald Global Healthcare Conference in New York on Wednesday, October 2nd, at 8:55am ET.

A webcast of the presentation will be available on the News and Events page of the company's website at http://www.biomx.com/news/. A replay of the webcast will be available approximately two hours after the event and archived on the website for 90 days.
About BiomX
BiomX is a preclinical stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as IBD, PSC, and cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.
On July 17th, 2019 BiomX announced that it has entered into a definitive agreement for a business combination with Chardan Healthcare Acquisition Corp. (NYSE: CHAC, "CHAC"), a special purpose acquisition company ("SPAC") sponsored by affiliates of Chardan Capital Markets LLC ("Chardan").
Media contactMacDougall Shai Biran, Ph.D.Direct: +1-781-235-3060 [email protected]
View original content to download multimedia:http://www.prnewswire.com/news-releases/biomx-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-300926579.html
SOURCE BiomX Ltd.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Thinking Machines Lab seeks $1b raise at $40b valuation - report
- Excelerate Energy to Participate in an Investor Conference
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Cantor Fitzgerald, Chardan Capital Markets, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share